Neural's Portfolio Company Hanf.com Expands Retail Footprint to Northern Germany with Two New Stores in Bielefeld and Herford
Toronto, Ontario--(Newsfile Corp. - November 6, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, together with its portfolio company CWE European Holdings Inc. ("CWE"), operating as Hanf.com, in which it owns 30.75% interest in, is pleased to announce the expansion of Hanf.com's retail network into northern...
2025-11-06 8:46 AM EST
Neural Portfolio Company Hanf.com Reports Strong Fiscal 2024 Results with 65% Revenue Growth, Positive Cash Flow and Double-Digit Operating Margin; Continued Growth in 2025; First Half Revenues Up 31% Year-Over-Year
Toronto, Ontario--(Newsfile Corp. - October 8, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on therapeutic solutions for mental health conditions, together with its portfolio company CWE European Holdings Inc. ("CWE", operating as Hanf.com), one of Germany's leading hemp- and CBD-based retail platforms, is pleased to report the audited financial results of Hanf.com for the fiscal year ended December 31,...
2025-10-08 9:37 AM EDT
Neural's Partner Hanf.com Expands Retail Footprint with 17th Store Opening Near Munich
Toronto, Ontario--(Newsfile Corp. - September 23, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for substance use disorders, together with CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CBD retailers, is pleased to announce the opening of its 17th retail location in the City of Freising, Bavaria. As disclosed in Neural's press...
2025-09-23 12:16 PM EDT
Neural Announces Completion of the Acquisition of a 30.75% Interest in Hanf.com, a Profitable German CBD Retail Store Chain
Toronto, Ontario--(Newsfile Corp. - August 13, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, and CWE European Holdings Inc. ("CWE"), the owner and operator of...
2025-08-13 7:30 AM EDT
Neural Announces Approval of the Strategic Investment and Option Agreement by CWE Shareholders to Acquire up to 100% of CWE
Toronto, Ontario--(Newsfile Corp. - July 22, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, and CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of the Germany's leading CBD retailers, are pleased to announce that all matters presented to shareholders of CWE, were approved at the special meeting of CWE...
2025-07-22 7:30 AM EDT
Neural Advances Ethnobotanical Strategy Through Execution of SERFOR Research Agreement and CWE's Exclusive German Distribution Agreement with Ritual Herbs
Toronto, Ontario--(Newsfile Corp. - July 21, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, is pleased to announce two major developments that strengthen its ethnobotanical strategy: (i) its German partner CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of the Germany's leading CBD retailers, has secured...
2025-07-21 8:53 AM EDT
Neural's Partner CWE to Open Store No. 16 in the City of Bonn and Invitation to Meet Hanf.com at Mary Jane Berlin 2025
Toronto, Ontario--(Newsfile Corp. - June 6, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, and CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of the Germany's leading CBD retailers, are pleased to provide an update on expansion efforts in Germany. A subsidiary of CWE has signed a franchise agreement to...
2025-06-06 7:30 AM EDT
Neural Therapeutics and Hanf.com Sign Strategic Investment and Option Agreement to Create a Science-Backed Botanical Wellness Leader
Toronto, Ontario--(Newsfile Corp. - May 28, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, and CWE European Holdings Inc. ("CWE"), operating as Hanf.com, a leading German CBD retailer, are pleased to announce the signing of a strategic investment and option agreement dated May 28, 2025 (the "SIO Agreement") for Neural...
2025-05-28 1:52 PM EDT
Neural Therapeutics Announces RSU and Options Grant
Toronto, Ontario--(Newsfile Corp. - May 13, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, announces that the Board of Directors approved the grant of 2,720,000 restricted share units ("RSUs") and 725,000 stock options ("Options").RSUs were granted to directors and consultants of Neural in accordance with the...
2025-05-13 4:31 PM EDT
Neural Therapeutics Announces SERFOR Permit Renewal Submission and Extension of LOI with HANF.COM
Toronto, Ontario--(Newsfile Corp. - May 9, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, is pleased to announce that it has submitted a renewal application to Servicio Nacional Forestal y de Fauna Silvestre ("SERFOR"). SERFOR a specialized Peruvian technical governmental agency under the Ministry of Agriculture,...
2025-05-09 8:26 AM EDT
Neural Therapeutics Strengthens IP Portfolio With a Patent Application
Toronto, Ontario--(Newsfile Corp. - April 14, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company dedicated to developing therapeutic drugs for mental illness
2025-04-14 8:52 AM EDT
Neural Therapeutics Commences Trading on Frankfurt Stock Exchange
Toronto, Ontario--(Newsfile Corp. - March 31, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: M6B) ("Neural" or the "Company"), an ethnobotanical drug discovery company dedicated to developing therapeutic drugs for mental illnesses related to substance use disorders, is pleased to announce that shares of the company have commenced trading on the Frankfurt Stock Exchange under ticker symbol "M6B".Neural CEO Ian Campbell commented, "Listing our shares on a Frankfurt Stock Exchange will...
2025-03-31 8:22 AM EDT
Neural Therapeutics Commences Trading, Provides Update on Growth Initiatives and Engages Investor Relations Consultants
Toronto, Ontario--(Newsfile Corp. - March 17, 2025) - Neural Therapeutics Inc. (CSE: NURL) ("Neural" or the "Company"), an ethnobotanical drug discovery company dedicated to developing therapeutic drugs for mental illnesses related to substance use disorders, is pleased to announce that its common shares will commence trading on the Canadian Securities Exchange ("CSE") under the symbol "NURL" on Monday, March 17, 2025.With the listing process completed and the Series A Financing closed,...
2025-03-17 7:30 AM EDT
Neural Therapeutics Announces Closing of Financing, CSE Listing Approval, Completion of Previously Announced Transactions and Corporate Updates
Toronto, Ontario--(Newsfile Corp. - March 13, 2025) - Neural Therapeutics Inc. ("Neural" or the "Company"), an ethnobotanical drug discovery company dedicated to developing therapeutic drugs for mental illnesses related to substance use disorders, is pleased to announce that it has completed the final tranche of its previously announced private placement ("Series A Financing") and has received conditional approval ("Conditional Approval") to list its common shares ("Neural Shares") on the...
2025-03-13 7:29 AM EDT
Neural Therapeutics Announces Changes to Board of Directors and Completion of Debt Settlement
Toronto, Ontario--(Newsfile Corp. - December 16, 2024) - Neural Therapeutics Inc. ("Neural" or the "Company"), an ethnobotanical drug discovery company dedicated to developing therapeutic drugs for mental illnesses related to substance use disorders, including alcohol and opioids, wishes to announce that Alex Storcheus and Eran Ovadya were appointed as directors to the Neural board.John Durfy, Chairman of Neural commented: "We are pleased to welcome Alex and Edan to Neural's board of...
2024-12-16 7:30 AM EST
Neural Therapeutics Undertakes Multiple Initiatives to Defer and Eliminate a Significant Portion of Financial Obligations
Toronto, Ontario--(Newsfile Corp. - November 25, 2024) - Neural Therapeutics Inc. ("Neural" or the "Company"), an ethnobotanical drug discovery company dedicated to developing therapeutic treatments for mental health conditions related to substance use disorders, is pleased to announce it has entered into a number of agreements with related parties and third parties that result in deferral and conversion of a significant amount of financial obligations, and elimination of certain general and...
2024-11-25 7:32 AM EST
Neural Therapeutics Inc. Announces Letter of Intent with Leading German Hemp-Based Product Retailer "Hanf.com"
Toronto, Ontario--(Newsfile Corp. - October 3, 2024) - Neural Therapeutics Inc. ("Neural" or the "Company"), an ethnobotanical drug discovery company dedicated to developing therapeutic treatments for mental health conditions related to substance use disorders, is pleased to announce that it has signed a non-binding letter of intent ("LOI") to acquire an interest in CWE European Holdings Inc., ("CWE" or "HANF"), a prominent hemp-based product retailer in Germany. CWE owns and operates both...
2024-10-03 7:32 AM EDT
Neural Therapeutics Announces Changes to Board of Directors and Advisors
Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Neural Therapeutics Inc. ("Neural" or the "Company"), an ethnobotanical drug discovery company dedicated to developing therapeutic drugs for mental illnesses related to substance use disorders, including alcohol and opioids, wishes to announce that Dr. Kelly Narine and Professor Jason Dyck have resigned as directors of Neural, and Dr. Carlos Davidovich was appointed as a new director.John Durfy, Chairman of Neural commented: "We extend our...
2024-06-27 12:00 PM EDT
Neural Therapeutics Receives Conditional Approval to Listing on the CSE and Announces Concurrent Financing
Toronto, Ontario--(Newsfile Corp. - May 8, 2024) - Neural Therapeutics Inc. ("Neural" or the "Company"), an ethnobotanical drug discovery company dedicated to developing therapeutic drugs for mental ailments related to substance use disorders, is pleased to announce that it has received conditional approval ("Conditional Approval") to list its common shares ("Neural Shares") on the Canadian Securities Exchange ("CSE") under the ticker symbol "NURL".Conditional Approval to List on the CSEThe...
2024-05-08 7:30 AM EDT
Neural Therapeutics Announces Board of Directors Appointments and IP Development Agreement with Validity Labs
Toronto, Ontario--(Newsfile Corp. - October 3, 2023) - Neural Therapeutics Inc. ("Neural" or the "Company") is pleased to announce the formal appointment of Dr. Jason Dyck, Dr. Kelly Narine and Colin McLelland to the Company's board of directors. The Company is also pleased to announce that it has entered into IP development agreement ("Agreement") with Validity Laboratory Services LLC ("Validity Labs").Ian Campbell, Neural CEO, commented, "While we've been collaborating with Dr. Narine, Dr,...
2023-10-03 7:30 AM EDT